Portal:CPTAC/Hallmark/Therapeutics
From WikiPathways
(Difference between revisions)
(adding WP4301) |
(added WP3844) |
||
| Line 8: | Line 8: | ||
*[[Pathway:WP4357]] NRF2-ARE regulation | *[[Pathway:WP4357]] NRF2-ARE regulation | ||
*[[Pathway:WP4301]] Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells | *[[Pathway:WP4301]] Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells | ||
| + | *[[Pathway:WP3844]] PI3K-AKT-mTOR signaling pathway and therapeutic opportunities | ||
Revision as of 01:56, 5 December 2018
- Pathway:WP3672 LncRNA-mediated mechanisms of therapeutic resistance
- Pathway:WP3640 Imatinib and Chronic Myeloid Leukemia
- Pathway:WP3614 Photodynamic therapy-induced HIF-1 survival signaling
- Pathway:WP3617 Photodynamic therapy-induced NF-kB survival signaling
- Pathway:WP3879 4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression
- Pathway:WP1601 Fluoropyrimidine Activity
- Pathway:WP3 Phytochemical activity on NRF2 transcriptional activation
- Pathway:WP4357 NRF2-ARE regulation
- Pathway:WP4301 Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells
- Pathway:WP3844 PI3K-AKT-mTOR signaling pathway and therapeutic opportunities
